BMS-986525
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BMS-986525, covering 2026-03-09 to 2026-03-09. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer [Phase 1, Phase 2]